Ruslan D. Novosiadly

发表

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

H. Maecker, S. Hu-Lieskovan, Yingdong Zhao, 2020, Journal for ImmunoTherapy of Cancer.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

P. Iversen, G. Plowman, Y. Webster, 2017, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

J. Haidar, M. Vieth, S. Eastman, 2017, Molecular Cancer Therapeutics.

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

T. Doman, M. Kalos, J. Manro, 2022, PloS one.

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

J. Haidar, M. Kalos, Leyi Shen, 2020, Molecular Cancer Therapeutics.

Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Tuan S. Nguyen, G. Scagliotti, S. Novello, 2016 .

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

High-content molecular profiling of T-cell therapy in oncology

M. Kalos, Ruslan D. Novosiadly, R. Novosiadly, 2016, Molecular therapy oncolytics.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

T. Doman, M. Morris, J. Durack, 2020, Clinical Cancer Research.

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Joon-Oh Park, H. Kim, S. Wong, 2019, Scientific Reports.